Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Hoffmann-La Roche
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Adult patients at least 18 years of age
Positive hepatitis C virus RNA at pre-transplantation
Primary, single-organ recipient (cadaveric donor)
Liver transplant between 10 and 16 weeks before treatment initiation
You may not be if
Multi-organ or re-transplant recipient
Evidence of current hepatitis B infection
Seropositive for human immunodeficiency (HIV) infection
Clareo Health | PHOENIX Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) and COPEGUS (Ribavirin) Administered After Liver Transplantation for Hepatitis C.
